Historique de carrière de Joanne Schindler
Anciens postes connus de Joanne Schindler
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| IMV INC. | Directeur Technique/Scientifique/R&D | 04/11/2019 | 11/06/2021 |
| FUSN PHAR | Directeur Technique/Scientifique/R&D | 30/06/2022 | - |
| Corporate Officer/Principal | - | 30/06/2022 | |
| CONSTELLATION PHARMACEUTICALS, INC. | Directeur Technique/Scientifique/R&D | - | - |
H3 Biomedicine, Inc.
 H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Directeur Technique/Scientifique/R&D | - | - |
Formation de Joanne Schindler
| The University of Connecticut School of Medicine | Doctorate Degree |
| Brandeis University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 5 |
| Canada | 3 |
Opérationnelle
| Chief Tech/Sci/R&D Officer | 4 |
| Doctorate Degree | 1 |
| Undergraduate Degree | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| IMV INC. | Health Technology |
| FUSN PHAR | Health Technology |
| Entreprise privées | 2 |
|---|---|
H3 Biomedicine, Inc.
H3 Biomedicine, Inc. Pharmaceuticals: MajorHealth Technology Part of Eisai Co., Ltd., H3 Biomedicine, Inc. is a precision oncology research and development subsidiary based in Cambridge, MA. The company is uniquely positioned to integrate real-world clinical evidence with the latest advances in cancer genomics. H3 is developing a pipeline of highly targeted, breakthrough medicines that have the potential to impact the future of cancer care and treatment. The CEO of the company is Takashi Owa. | Health Technology |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Constellation Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics in the field of epigenetics. The firm utilizes epigenetics platform, which enables to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. Its product include CPI-0610, CPI-1205, and CPI-0209. The company was founded by Danny Reinberg, David Allis, and Yang Shi on January 11, 2008 and is headquartered in Cambridge, MA. | Health Technology |
- Bourse
- Insiders
- Joanne Schindler
- Expérience
